ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08955
0,26%
Bitcoin
66.767,08
2,34%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. Vereinigtes Königreich
  5. LSE
  6. Calliditas Therapeutics Ab (0A5R)

  7. Calliditas Therapeutics Ab (0A5R) News

0A5R

Calliditas Therapeutics Ab (0A5R)

Calliditas Therapeutics Ab
Von:
Sortieren nach:
 Showing the most relevant articles for your search:LSE:0A5R
DatumZeitQuelleÜberschriftSymbolFirma
18/08/202310h21PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
18/08/202310h17PR Newswire (US)FDA grants priority review for full approval of TARPEYO for the treatment of IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
17/08/202307h29PR Newswire (US)Interim Report Q2, 2023: Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
15/08/202310h52PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
15/08/202310h50PR Newswire (US)Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The LancetLSE:0A5RCalliditas Therapeutics Ab
13/07/202308h20PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
13/07/202308h17PR Newswire (US)Calliditas announces supportive interim data from Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxibLSE:0A5RCalliditas Therapeutics Ab
21/06/202310h12PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
21/06/202310h10PR Newswire (US)Calliditas Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Full Approval of TARPEYO®LSE:0A5RCalliditas Therapeutics Ab
30/05/202316h18PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
30/05/202316h16PR Newswire (US)Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
16/05/202307h17PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
16/05/202307h14PR Newswire (US)Calliditas Therapeutics: Interim Report Q1, 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/202315h01PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
05/05/202315h00PR Newswire (US)Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023LSE:0A5RCalliditas Therapeutics Ab
28/04/202310h54PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
28/04/202310h51PR Newswire (US)Notice of annual general meeting of Calliditas Therapeutics AB (publ)LSE:0A5RCalliditas Therapeutics Ab
27/04/202304h40PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
27/04/202300h15PR Newswire (US)Calliditas Therapeutics' 2022 Annual Report PublishedLSE:0A5RCalliditas Therapeutics Ab
31/03/202317h24PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
31/03/202317h20PR Newswire (US)Calliditas to participate in upcoming investor conferencesLSE:0A5RCalliditas Therapeutics Ab
13/03/202304h15PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
13/03/202304h06PR Newswire (US)Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
23/02/202307h41PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
23/02/202307h34PR Newswire (US)Calliditas - Year-End Report, 2022LSE:0A5RCalliditas Therapeutics Ab
02/02/202309h46PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
02/02/202309h44PR Newswire (US)Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathyLSE:0A5RCalliditas Therapeutics Ab
31/01/202308h22PR Newswire (US)Number of shares and votes in Calliditas TherapeuticsLSE:0A5RCalliditas Therapeutics Ab
30/12/202209h03PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
30/12/202209h00PR Newswire (US)China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA NephropathyLSE:0A5RCalliditas Therapeutics Ab
 Showing the most relevant articles for your search:LSE:0A5R

Kürzlich von Ihnen besucht

AMEX
XLV
Health Care Select Sector
TG
D7G
Nel ASA
DBI
DAX
DAX
NYSE
NKE
Nike
TG
DTE
Deutsche Telekom
TG
LHA
Deutsche Lufthansa
NYSE
MRK
Merck
TG
BAYN
Bayer
DBI
TDXP
Tec DAX
FX
EURUSD
Euro vs US Dollar
DBI
SDXP
SDAX
USOTC
BNPQY
BNP Paribas (QX)
PM
XAUUSD
Gold vs US Dollar
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten